The patent for semaglutide, a key component in medications such as Ozempic, is set to expire, leading to expectations for cheaper national alternatives in Brazil. However, these alternatives are not expected to reach pharmacies immediately. Regulatory bodies, including the Brazilian National Health Surveillance Agency (ANVISA), are currently reviewing 15 applications for national versions, but none have been approved so far. While the expiration of the patent should pave the way for more affordable options in the future, the complex nature of the drug complicates and delays the approval process.

Semaglutide, originally patented by Novo Nordisk for 20 years, faced a legal challenge from the company in an attempt to extend its exclusivity by another 12 years, but the court ruled against them. This ruling has sparked interest from other pharmaceutical companies, which are now working on developing their own versions of the medication. The market is eager for more affordable treatments, especially given the growing recognition of semaglutide's effectiveness for weight management and diabetes treatment.

Experts indicate that the development and approval of new generics and alternatives depend on a lengthy regulatory process. They note that the complexity of semaglutide as a peptide plays a significant role in this delay. The eventual arrival of these alternatives could significantly impact access to treatment, particularly for patients in Brazil who rely on these medications for managing their health conditions. Better access to affordable medications might improve health outcomes for many individuals once these alternatives are on the market.